Dr Reddy's Laboratories SG&A Expenses 2010-2024 | RDY

Dr Reddy's Laboratories annual/quarterly sg&a expenses history and growth rate from 2010 to 2024. Sg&a expenses can be defined as the sum of all selling, general and administrative expenses.
  • Dr Reddy's Laboratories sg&a expenses for the quarter ending June 30, 2024 were $0.272B, a 25.93% increase year-over-year.
  • Dr Reddy's Laboratories sg&a expenses for the twelve months ending June 30, 2024 were $982M, a 15.8% increase year-over-year.
  • Dr Reddy's Laboratories annual sg&a expenses for 2024 were $0.926B, a 11.84% increase from 2023.
  • Dr Reddy's Laboratories annual sg&a expenses for 2023 were $0.828B, a 1.22% increase from 2022.
  • Dr Reddy's Laboratories annual sg&a expenses for 2022 were $0.818B, a 9.5% increase from 2021.
Dr Reddy's Laboratories Annual SG&A Expenses
(Millions of US $)
2024 $926
2023 $828
2022 $818
2021 $747
2020 $665
2019 $707
2018 $720
2017 $715
2016 $690
2015 $683
2014 $622
2013 $616
2012 $567
2011 $532
2010 $501
2009 $
Dr Reddy's Laboratories Quarterly SG&A Expenses
(Millions of US $)
2024-06-30 $272
2024-03-31 $241
2023-12-31 $243
2023-09-30 $226
2023-06-30 $216
2023-03-31 $206
2022-12-31 $219
2022-09-30 $207
2022-06-30 $196
2022-03-31 $193
2021-12-31 $207
2021-09-30 $215
2021-06-30 $202
2021-03-31 $204
2020-12-31 $197
2020-09-30 $177
2020-06-30 $169
2020-03-31 $73
2019-12-31 $179
2019-09-30 $238
2019-06-30 $175
2019-03-31 $186
2018-12-31 $167
2018-09-30 $177
2018-06-30 $177
2018-03-31 $179
2017-12-31 $187
2017-09-30 $172
2017-06-30 $182
2017-03-31 $189
2016-12-31 $167
2016-09-30 $177
2016-06-30 $182
2016-03-31 $164
2015-12-31 $183
2015-09-30 $170
2015-06-30 $173
2015-03-31 $142
2014-12-31 $172
2014-09-30 $176
2014-06-30 $178
2014-03-31 $159
2013-12-31 $169
2013-09-30 $146
2013-06-30 $148
2013-03-31 $169
2012-12-31 $159
2012-09-30 $143
2012-06-30 $145
2012-03-31 $119
2011-12-31 $141
2011-09-30 $158
2011-06-30 $149
2011-03-31 $154
2010-12-31 $142
2010-09-30 $118
2010-06-30 $118
2010-03-31 $153
2009-12-31 $117
2009-09-30 $108
2009-06-30 $123
2009-03-31 $65
Sector Industry Market Cap Revenue
Medical Medical - Generic Drugs $12.329B $3.350B
Dr. Reddy's Laboratories Ltd. is an integrated global pharmaceutical company engaged in providing affordable and innovative medicines since 1984. The company markets its products in countries like the U.S., the UK, Germany, India, Russia, Venezuela, Romania and South Africa. Dr. Reddy's operates through three segments: Global Generics comprising unbranded prescription drugs along with over-the-counter drugs. It includes the operations of the company's biologics business. Pharmaceutical Services & Active Ingredients (PSAI) comprising active pharmaceutical ingredients (API) and custom pharmaceutical services. Proprietary Products and Others involving the new chemical entities, the differentiated formulations business and a dermatology specialty business. The company has a strategic partnership with Glaxo to market selected products across emerging markets outside India.
Stock Name Country Market Cap PE Ratio
Teva Pharmaceutical Industries (TEVA) Israel $19.384B 6.36
BridgeBio Pharma (BBIO) United States $4.629B 0.00
Bausch Health Cos (BHC) Canada $3.358B 2.43
Amphastar Pharmaceuticals (AMPH) United States $2.294B 13.79
Supernus Pharmaceuticals (SUPN) United States $2.089B 28.44
Taysha Gene Therapies (TSHA) United States $0.490B 79.67
Personalis (PSNL) United States $0.278B 0.00
Assembly Biosciences (ASMB) United States $0.105B 0.00
Sol-Gel Technologies (SLGL) Israel $0.016B 0.00
Evoke Pharma (EVOK) United States $0.004B 0.00
Teligent (TLGT) United States $0.000B 0.00